Evidence map›Paper›PMID 41121528›Full record

ArticleG3 (Bethesda, Md.)2026

CrisprBuildr: an open-source application for CRISPR-mediated genome engineering in Drosophila melanogaster.

Nicole Horsley, Adam von Barnau Sythoff, Mark Delgado, Selina Liu, Clemens Cabernard

Abstract read
In one paragraph

Article in G3 (Bethesda, Md.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Altering cell size asymmetry inbioRxiv : the preprint server for biology · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Nicole HorsleyDepartment of Biology, University of Washington, Life Science Building, Seattle WA 98195, United States.
Adam von Barnau SythoffDepartment of Biology, University of Washington, Life Science Building, Seattle WA 98195, United States.
Mark Delgado
Selina LiuDepartment of Biology, University of Washington, Life Science Building, Seattle WA 98195, United States.
Clemens CabernardDepartment of Biology, University of Washington, Life Science Building, Seattle WA 98195, United States.ORCID 0000-0003-3706-6401

Funding

Resource Component: Acquisition, maintenance and distribution of Drosophila stocksP40OD018537 · OD · TRUSTEES OF INDIANA UNIVERSITY · PI Annette L. Parks · 2014 to 2026
$13.5M
Cell and mechanobiology of Asymmetric Cell DivisionR35GM148160 · NIGMS · UNIVERSITY OF WASHINGTON · PI Clemens C Cabernard · 2023 to 2026
$1.7M
NIGMS NIH HHS R35 GM148160NIH HHS P40 OD018537NIH HHS R35GM148160
6 · The paper itself

Abstract

CRISPR/Cas9 is a powerful tool for targeted genome editing experiments. Using CRISPR/Cas9, genes can be deleted or modified by inserting specific DNA sequences, encoding for fluorescent proteins, small peptide tags, or other modifications. Such experiments are essential for detailed gene and protein characterization. However, designing and cloning the corresponding constructs can be repetitive, time-consuming, and laborious. To assist users in CRISPR/Cas9-based genome engineering, we developed CrisprBuildr, an open-source, web-based application for designing modifications to their target genes. CrisprBuildr guides users through creating guide RNAs and repair template vectors to generate cloning maps. The application is designed for the Drosophila melanogaster genome but can serve as a template for other available genomes. We also created new tagging vectors using EGFP and mCherry combined with the small peptide SspB-Q73R for use in iLID-based optogenetic experiments.

Indexed as

CRISPR-Cas SystemsDrosophila melanogasterGene EditingGenetic EngineeringGenome, InsectSoftwareAnimalsClustered Regularly Interspaced Short Palindromic RepeatsRNA, Guide, CRISPR-Cas SystemsRNA, Guide, CRISPR-Cas SystemsCRISPRDrosophilagenome engineering

Identifiers

PMID41121528
PMCPMC12774585

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.